See more : Restaurant Brands New Zealand Limited (RBD.NZ) Income Statement Analysis – Financial Results
Complete financial analysis of Arvinas, Inc. (ARVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arvinas, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FIFAX Abp (FIFAX.HE) Income Statement Analysis – Financial Results
- HWASHIN CO.,Ltd (010690.KS) Income Statement Analysis – Financial Results
- Lyric Jeans, Inc. (LYJN) Income Statement Analysis – Financial Results
- Oil Refineries Ltd. (OILRF) Income Statement Analysis – Financial Results
- PT Wulandari Bangun Laksana Tbk (BSBK.JK) Income Statement Analysis – Financial Results
Arvinas, Inc. (ARVN)
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 78.50M | 131.40M | 46.70M | 21.80M | 42.98M | 14.32M | 7.58M | 6.67M |
| Cost of Revenue | 0.00 | 8.20M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 78.50M | 123.20M | 40.70M | 21.80M | 42.98M | 14.32M | 7.58M | 6.67M |
| Gross Profit Ratio | 100.00% | 93.76% | 87.15% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 379.70M | 315.00M | 180.40M | 108.36M | 67.19M | 45.19M | 28.79M | 19.94M |
| General & Administrative | 100.30M | 79.60M | 61.60M | 38.30M | 27.31M | 12.93M | 3.55M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.30M | 79.60M | 61.60M | 38.30M | 27.31M | 12.93M | 3.55M | 3.20M |
| Other Expenses | 0.00 | 200.00K | 2.50M | 2.00M | 1.44M | 102.73K | 554.16K | 1.66M |
| Operating Expenses | 480.00M | 394.60M | 242.00M | 146.66M | 94.50M | 58.13M | 32.34M | 23.14M |
| Cost & Expenses | 480.00M | 394.60M | 242.00M | 146.66M | 94.50M | 58.13M | 32.34M | 23.14M |
| Interest Income | 38.80M | 12.20M | 4.30M | 5.53M | 5.91M | 2.32M | 201.39K | 427.77K |
| Interest Expense | 0.00 | 12.00M | 100.00K | 65.00K | 85.57K | 57.44K | 50.36K | 67.40K |
| Depreciation & Amortization | 6.70M | 8.20M | 6.00M | 4.02M | 2.25M | 706.00K | 347.40K | 436.33K |
| EBITDA | -394.80M | -256.90M | -183.60M | -117.60M | -67.95M | -40.72M | -23.65M | -13.93M |
| EBITDA Ratio | -502.93% | -200.30% | -418.20% | -572.69% | -119.89% | -305.80% | -312.15% | -209.16% |
| Operating Income | -401.50M | -263.20M | -195.30M | -124.86M | -51.52M | -43.80M | -24.76M | -16.47M |
| Operating Income Ratio | -511.46% | -200.30% | -418.20% | -572.69% | -119.89% | -305.80% | -326.70% | -246.95% |
| Total Other Income/Expenses | 37.60M | 12.20M | -2.60M | 1.50M | -18.79M | 2.32M | 711.06K | 2.03M |
| Income Before Tax | -363.90M | -251.00M | -191.00M | -119.33M | -70.29M | -41.48M | -24.05M | -14.44M |
| Income Before Tax Ratio | -463.57% | -191.02% | -408.99% | -547.35% | -163.56% | -289.59% | -317.32% | -216.49% |
| Income Tax Expense | 900.00K | 20.90M | -7.80M | -7.55M | -8.16M | 2.38M | 604.52K | -87.41K |
| Net Income | -367.30M | -271.90M | -183.20M | -111.79M | -62.13M | -41.48M | -24.05M | -14.35M |
| Net Income Ratio | -467.90% | -206.93% | -392.29% | -512.74% | -144.57% | -289.59% | -317.32% | -215.18% |
| EPS | -6.62 | -5.11 | -3.66 | -2.83 | -1.89 | -4.40 | -1.16 | -0.80 |
| EPS Diluted | -6.62 | -5.11 | -3.66 | -2.83 | -1.89 | -4.40 | -1.16 | -0.80 |
| Weighted Avg Shares Out | 55.50M | 53.20M | 50.00M | 39.53M | 32.93M | 9.42M | 20.73M | 17.88M |
| Weighted Avg Shares Out (Dil) | 55.50M | 53.20M | 50.00M | 39.53M | 32.93M | 9.42M | 20.73M | 17.88M |
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and...
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. I highlight...
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral...
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual...
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to loss of $1.54 per share a year ago.
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting –
Why Earnings Season Could Be Great for Arvinas (ARVN)
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Source: https://incomestatements.info
Category: Stock Reports